Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.
Chronic myeloid leukemia ( CML ) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR - ABL tyrosine kinase . Imatinib ( STI571 ) , selective inhibitor of the ABL - tyrosine kinase , inhibits the activity of BCR - ABL tyrosine kinase . A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon - refractory CML , offering new hope for therapy for CML . It will , however , require long - term follow - up data from phase II and III clinical studies to validate the effect of STI571 on survival . As therapy for CML improves , monitoring minimal residual disease will be important .
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?
What tyrosine kinase , involved in a Philadelphia- chromosome positive chronic myelogenous leukemia , is the target of Imatinib ( Gleevec ) ?
BCR-ABL
BCR-ABL